ストックスクリーナーアプリを入手
0.405
1.03%
-0.0043
前日終値:
$0.4093
開ける：
$0.407
24時間の取引高:
170.39K
Relative Volume:
0.06
時価総額：
$4.46M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-13.07%
1か月 パフォーマンス:
-42.13%
6か月 パフォーマンス:
-99.44%
1年 パフォーマンス:
-99.93%
1日の値動き範囲:
$0.375
$0.4243
1週間の範囲:
$0.375
$0.47
52週間の値動き範囲:
$0.375
$604.80
AEON Biopharma Inc. Stock (AEON) Company Profile
AEON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.405 | 4.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.76 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
548.71 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
582.04 | 35.29B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.37 | 29.62B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.65 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-18 | 開始されました | H.C. Wainwright | Buy |
AEON Biopharma Inc. (AEON) 最新ニュース
AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia
AEON Biopharma Appoints Jost Fischer as Interim CEO - TipRanks
AEON Biopharma announces new interim CEO and CFO - Investing.com
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1 - NewsBreak: Local News & Alerts
AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines
Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal
AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener
AEON Biopharma announces leadership change amid growth strategy - Investing.com
AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks
AEON Biopharma Announces CEO Transition - The Manila Times
Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan
AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025 - News & Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025 - Nasdaq
AEON's $20M Cash Injection Powers Game-Changing BOTOX Alternative Development - Stock Titan
AEON Biopharma (NASDAQ:AEON) Stock Price Down 7.6% – Should You Sell? - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Understanding AEON’s financial ratios: A beginner’s guide - US Post News
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma : Corporate Presentation -March 10, 2025 at 06:26 am EDT - Marketscreener.com
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference - The Manila Times
AEON CEO to Showcase Botulinum Toxin Pipeline at Major Healthcare Conference - StockTitan
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
Cervical Dystonia Market Expected to Experience Major Growth - openPR
AEON stock touches 52-week low at $0.76 amid market shifts - Investing.com
AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine - Marketscreener.com
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine -May 03, 2024 at 07:00 am EDT - MarketScreener
AEON Biopharma, Inc. Announces Executive Changes -May 16, 2024 at 04:28 pm EDT - MarketScreener
AEON Biopharma, Inc. Announces Strategic Reprioritization to Pursue A Biosimilar Pathway for ABP-450 - Marketscreener.com
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - MarketScreener
AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - MarketScreener
Stock market news: AEON Biopharma plummented by 65.33% while Enveric Biosciences skyrocketed by 90.68% during midday trading - Business Upturn
Stock market today: AEON Biopharma plunged by 63.17% while Enveric Biosciences surged by 124.66% in early trading - Business Upturn
AEON Biopharma To Implement 1-for-72 Reverse Stock Split For Compliance With NYSE Rules - Nasdaq
AEON Biopharma, Inc. Announces Reverse Stock Split - The Manila Times
AEON Biopharma executes reverse stock split to comply with NYSE standards - Investing.com Australia
Aeon Biopharma Approves 1-For-72 Reverse Stock Split -February 24, 2025 at 02:53 pm EST - Marketscreener.com
AEON Biopharma shares plunge as it announces reverse stock split - MSN
AEON Biopharma Stockholders Approve Key Proposals - TipRanks
AEON Biopharma Announces 1-for-72 Reverse Stock Split Effective February 26, 2025 - Nasdaq
Aeon to Implement 1-for-72 Reverse Stock Split; Shares Fall - MarketScreener
AEON Biopharma Inc (AEON) Shares Down Despite Recent Market Volatility - The News Heater
Watch this stock’s price performance: AEON Biopharma Inc (AMEX:AEON) - US Post News
AEON Biopharma Receives Notice Of Non-Compliance With NYSE American Listing Standards - Nasdaq
AEON Biopharma Inc (AMEX: AEON) Could See A Rise In Prices Shortly. - Marketing Sentinel
Investor’s Delight: AEON Biopharma Inc (AEON) Closes Weak at 0.13, Down -6.93 - The Dwinnex
AEON Biopharma receives NYSE non-compliance notice - MSN
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma Inc. (AEON) 財務データ
AEON Biopharma Inc. (AEON) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.44%
0.27%
大文字化:
|
ボリューム (24 時間):